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Abstract
Background: Advanced gastric cancer in the lower third of the stomach often results in stricture of the gastric
cavity and digestive symptoms. Gastrojejunostomy has been suggested to improve such symptoms, and the advent
of new anticancer agents for gastric cancer has improved the response rate of the disease, which makes it possible
to perform R0 gastrectomy in part of patients with stage IV gastric cancer. We experienced a rare case in which a
patient with stage IV gastric cancer and cancerous pyloric stenosis was treated with R0 surgery after undergoing a
gastrojejunal bypass procedure and multidisciplinary treatment. There have not been any previous reports about
cases in which a previous gastrojejunostomy was utilized as a reconstruction route during distal gastrectomy in a
patient with gastric cancer that had been treated with chemotherapy and/or CRT.
Case presentation: An 80-year-old female with advanced gastric cancer and pyloric stenosis was admitted to
Kagoshima University Hospital. As peritoneal washing cytology produced a positive result, laparoscopic
gastrojejunostomy (modified Devine procedure) was performed to improve food passage, and S-1 (100 mg/body,
days 1–14) plus paclitaxel (120 mg/body, days 1 and 15) was administered. Although the tumor was temporarily
reduced in size, an abdominal computed tomography scan obtained after four courses of chemotherapy showed
progressive disease. Thus, chemoradiotherapy (56 Gy, S-1: 60 mg/body, CDDP: 5 mg/body, days 1–5) was indicated.
Marked tumor shrinkage and negative peritoneal washing cytological results were achieved. Curative gastrectomy
with D2 lymphadenectomy was performed. We carried out distal gastrectomy and lymph node dissection, and the
gastrojejunostomy produced as a gastric bypass in the previous operation was preserved. The patient has not
suffered a tumor relapse in 4 years since the surgery.
Conclusions: We surgeons increase a chance to perform R0 gastrectomy for stage IV gastric cancer following
intensive chemotherapy and/or CRT. We should choose proper position of gastrojejunostomy in producing
alimentary bypass for stage IV gastric cancer patients to facilitate curative surgery.
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Background
Intensive chemotherapy is indicated for stage IV gastric
cancer, and its effects determine patient outcomes. Sev-
eral reports have demonstrated the potential of S-1 as a
treatment for advanced or recurrent gastric cancer in
Japan [1]. Advanced gastric cancer in the lower third of
the stomach often results in stricture of the gastric cavity
and digestive symptoms such as appetite loss and vomit-
ing. Gastrojejunostomy has been suggested to improve
such symptoms [2]. The advent of new anticancer agents
for gastric cancer has improved the response rate of the
disease and has made it possible to destroy distant le-
sions [3–6]. Intensive chemotherapy might make it pos-
sible to perform R0 gastrectomy in part of patients with
stage IV gastric cancer. In such cases, a gastrojejunost-
omy that was produced as a bypass might be used as a
reconstruction route after curative gastrectomy.
We present a rare case of stage IV gastric cancer, in
which curative surgery was performed after multidisciplin-
ary treatment. A previous gastrojejunostomy was utilized
as a reconstruction route during the curative procedure.
Case presentation
An 80-year-old woman was admitted to Kagoshima Uni-
versity Hospital with a chief complaint of epigastralgia.
Gastroscopy revealed type 3 gastric cancer in the lesser
curvature of the antrum (Fig. 1). The pathological diagnosis
of the biopsy specimen was poorly differentiated adenocar-
cinoma. Abdominal computed tomography (CT) revealed
thickening of the antrum wall, 70 mm in diameter, and
suggested that perigastric lymph node metastases were
present. A blood test showed serious anemia (Hb 4.7 g/dl),
and the patient’s carcinoembryonic antigen and carbohy-
drate antigen 19-9 levels were normal. The patient under-
went a staging laparoscopy under general anesthesia, and
perioperative washing cytology of her ascites produced a
positive result. She was diagnosed with stage IV gastric
cancer, and a gastrojejunostomy was produced in the mid-
dle third of her stomach to improve food passage. The
status of gastric cancer was cT4a(SE)N2H0P0CY1 cStageIV
(based on Japanese classification of gastric carcinoma [7]).
Therefore, a combination of S-1 (100 mg/body, days
1–14) plus paclitaxel (120 mg/body, days 1 and 15) was
administered. Although the tumor was temporarily reduced
in size, gastroscopy and abdominal CT showed tumor
regrowth after four courses of chemotherapy (Fig. 2). How-
ever, a preoperative peritoneal washing cytology produced a
negative result (CY0) so chemoradiotherapy (CRT; total
dose 56 Gy, S-1: 60 mg/body, CDDP: 5 mg/body, days 1–5)
was started for the purpose of local control. The CRT re-
sulted in marked tumor and nodal shrinkage, as determined
by CT and gastroscopy (Fig. 3), and preoperative peri-
toneal washing cytology continued to produce negative
results (CY0). Then, distal gastrectomy with D2 lymphade-
nectomy was performed with curative intent. The stomach
was resected on the distal side of the gastric bypass, and
the gastrojejunostomy was reused as a route for the
reconstruction of the remnant stomach and jejunum (Fig. 4).
Macroscopically, the gastric lesion in the resected specimen
Fig. 1 Endoscopic findings before the first operation. Gastroscopy revealed type 3 gastric cancer and pyloric stenosis in the lesser curvature of the antrum
Fig. 2 Endoscopic findings after chemotherapy. Regrowth of the
gastric cancer was observed after four courses of chemotherapy
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was scarred (Fig. 5). The pathological diagnosis was
poorly differentiated adenocarcinoma, 10 × 5 mm, ypT3(SS),
ly1,v-,N0,M0 ypStageIIA. Pathological examination revealed
the proper muscular layer had disappeared, which had been
replaced by the fibrous tissue in the center of scar. A few vi-
able cancer cells were found in the tumor nest, so histo-
logical effect by the CRT was evaluated as grade 2 according
to the Japanese classification of gastric carcinoma [7].
The patient’s postoperative course was uneventful. Be-
cause of a low level of white blood cell, she has been
followed closely without adjuvant therapy. Four years after
the operation, she is well, and the tumor has not relapsed.
Discussion
The initial regimen used to treat this patient involved bi-
weekly paclitaxel plus S-1. This regimen was originally
established in our department [8, 9], and Nakajo et al.
reported that it resulted in a response rate of 43.6% and a
median survival time of 268 days, which are not inferior
to those of the standard regimen for gastric cancer. More-
over, elderly patients are able to tolerate this approach and
have been repeatedly treated with this regimen. In the
present case, this chemotherapy regimen resulted in the
disappearance of cytological positivity.
As the patient’s tumor was resistant to the first regi-
men, we chose to treat the patient with CRT after con-
firming that her distant metastases were under control.
The use of second-line chemotherapy after the failure of
first-line chemotherapy seems to be a common approach
to the treatment of advanced gastric cancer. Hironaka et
al. [10] suggested the clinical usefulness of second-line
chemotherapy for stage IV gastric cancer. However, the
response rate was lower than 21%, which was signifi-
cantly lower than that for first-line chemotherapy.
CRT is included in the current standard regimen for
advanced gastric cancer. Ajani et al. [11] reported that
combined treatment involving radiotherapy and chemo-
therapy (5-FU plus cisplatin) in a neoadjuvant setting pro-
duced a R0 resection rate of 77% and a pathological
complete response rate of 26%. Moreover, in Japan, Sai-
kawa et al. [12] reported a markedly high response rate in
a phase II study of CRT involving S-1 and cisplatin for
unresectable gastric cancer. Finally, we found that CRT
had a markedly beneficial histological effect on gastric can-
cer. It is suggested that CRT is a possible second-line ther-
apy for advanced or recurrent gastric cancer. Therefore,
multidisciplinary treatment involving CRT might be useful
as a second-line treatment for locally advanced gastric
cancer.
Three surgical strategies have been indicated for gastric
cancer patients with cancerous obstruction: palliative gas-
trectomy, an alimentary bypass, and stent insertion. Patients
that exhibit a good performance status are often indicated
for gastrojejunostomy to produce an alimentary bypass [2].
Fig. 3 Endoscopic findings after chemoradiotherapy. Chemoradiotherapy
resulted in marked tumor shrinkage
Fig. 4 Distal gastrectomy. Gastrojejunostomy was reused to reconstruct the remnant stomach and jejunum
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Simple gastrojejunostomy often concomitant with delayed
gastric emptying and bleeding from the tumor surface [13].
Devine et al. introduced the novel gastrojejunal bypass with
a transection between the tumor and gastrojejunostomy to
prevent such complications [14]. Schantz et al. [15] reported
of modified Devine procedure with hemitransection of the
stomach, which allows endoscopic examination. Therefore,
modified Devine procedure seems to be suitable for stage
IV gastric cancer patients planning to receive intensive
chemotherapy and/or CRT like the current case. As a result,
her pyloric stenosis improved, and she was able to receive
treatment as an outpatient. The use of a laparoscopic ap-
proach during gastrojejunostomy is becoming increasingly
common. In a previous series, we performed gastrojejunost-
omy after staging laparoscopy [16]. At the first surgery, we
paid attention to keep a good margin from the tumor to
produce gastrojejunostomy.
In the second surgical procedure, we simply resected
the distal stomach and lymph nodes, and we were able
to utilize the gastrojejunostomy produced during the
first surgical procedure.
There have not been any previous reports about cases
in which a previous gastrojejunostomy was utilized as a
reconstruction route during distal gastrectomy in a patient
with gastric cancer that had been treated with chemother-
apy and/or CRT.
Conclusions
We surgeons increase a chance to perform R0 gastrectomy
for stage IV gastric cancer following intensive chemother-
apy and/or CRT. We should choose proper position of
gastrojejunostomy in producing alimentary bypass for stage
IV gastric cancer patients to facilitate curative surgery.
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